Horton, a fourth-round pick by the Texans in 2023, played in 10 games as a rookie before stepping away from the team in late ...

Patients with a rare blood cancer that has relapsed or become resistant to treatment have shown a high response rate to a ...

Nurse Dalton Cummins can truly relate to his oncology patients at Riley Hospital for Children. After all, he was once a ...

A recent study derived from the adverse event reporting system of the Food and Drug Administration (FDA) showed that T-cell non-Hodgkin lymphomas were identified in 17 of 536 reports (3.2% ...

July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...

India continues to see a steady rise in the incidence of lymphoma, the most common type of blood cancer. But among all the ...

Houston Texans defensive end Dylan Horton was activated from the reserve/non-football injured list Saturday, less than a year after he was diagnosed with late-stage Hodgkin lymphoma ...

September is Leukemia & Lymphoma Awareness Month. Oncologists diagnosed Skarzinski with stage 4 non-Hodgkin's B cell Lymphoma ...

Cambridge: AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim findings from three real-world studies in cutaneous ...

Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T ...